<DOC>
	<DOCNO>NCT02823145</DOCNO>
	<brief_summary>This international , multicenter , open-label , long-term safety study ZX008 pediatric young adult subject Dravet syndrome successfully complete 14 week treatment core study ( ZX008-1501 ZX008-1502 ) .</brief_summary>
	<brief_title>An Open-Label Extension Trial Assess Long-Term Safety ZX008 ( Fenfluramine Hydrochloride HCl ) Oral Solution Children Young Adults With Dravet Syndrome</brief_title>
	<detailed_description>This international , multicenter , open-label , long-term safety study ZX008 pediatric young adult subject Dravet syndrome successfully complete 14 week treatment one core study ( ZX008-1501 ZX008-1502 ) candidate continuous treatment extend period time . Subjects permit participate present study complete final evaluation Day 113 one core study . This trial consist 12-month Open-Label Extension ( OLE ) Treatment Period 2-week Post-Dosing Period . Thus , subject complete trial treat ZX0008 minimum 1 year ( include participation core study study ) .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Epilepsies , Myoclonic</mesh_term>
	<mesh_term>Fenfluramine</mesh_term>
	<criteria>Key Male nonpregnant , nonlactating female , age 2 18 year , inclusive day core study Screening Visit . Satisfactory completion core study opinion investigator sponsor . A documented medical history support clinical diagnosis Dravet syndrome , convulsive seizure completely control current antiepileptic drug . Parent/caregiver willing able compliant diary completion , visit schedule study drug accountability . Subject 's parent/caregiver compliant diary completion core study , opinion investigator ( eg , least 90 % compliant ) . Key Current past history cardiovascular cerebrovascular disease , myocardial infarction stroke . Current cardiac valvulopathy pulmonary hypertension investigator , parent , IPCAB , IDSMC , sponsor deems clinically significant warrant discontinuation study medication . Current past history glaucoma . Moderate severe hepatic impairment . Receiving concomitant therapy : centrallyacting anorectic agent ; monoamineoxidase inhibitor ; centrallyacting compound clinically appreciable amount serotonin agonist antagonist property , include serotonin reuptake inhibition ; atomoxetine , centrallyacting noradrenergic agonist ; cyproheptadine , and/or cytochrome P450 ( CYP ) 2D6/3A4/2B6 inhibitors/substrates . Currently take carbamazepine , oxcarbamazepine , eslicarbazepine , phenobarbital , phenytoin , take within past 30 day , maintenance therapy . Currently receive receive stiripentol past 21 day prior Visit 1 . Unwilling refrain large daily serving grapefruit and/or Seville orange , juice begin Visit 1 throughout study . A clinically significant condition , clinically relevant symptom clinically significant illness Visit 1 , epilepsy , would negatively impact study participation , collection study data , pose risk subject .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>seizure</keyword>
	<keyword>tonic clonic</keyword>
	<keyword>epilepsy</keyword>
	<keyword>myoclonic</keyword>
	<keyword>encephalopathy</keyword>
</DOC>